Introduction {#Sec1}
============

The use of antibiotics is associated with disorders of gastrointestinal tract function and diarrhoea in 5--39% patients \[[@CR1], [@CR2]\]. *Clostridium difficile* (*C. difficile*) is a common infectious cause of antibiotic-associated diarrhoea (AAD) \[[@CR1]--[@CR4]\]. *C. difficile* is capable of producing an enterotoxin (toxin A) and a cytotoxin (toxin B). Express laboratory tests for glutamate dehydrogenase (GDH) and free *C. difficile* toxins in stool are used for the diagnosis of *C. difficile*-associated diarrhoea (CDAD) \[[@CR5]\].

Reports from other countries indicate that CDAD is becoming more common and requires special attention due to the risk of serious complications, including fatalities \[[@CR6]--[@CR9]\]. Russian clinical data on the epidemiology of CDAD are limited to individual retrospective--prospective single-centre studies \[[@CR10]--[@CR13]\]. Due to the limited number of Russian studies dedicated to CDAD, further research on this issue within a Russian prospective multicentre epidemiological study is of scientific and clinical interest.

The objective of the study was to determine the prevalence of CDAD in hospitalised patients with antibiotic-associated diarrhoea (AAD) in general and in subgroups of patients from wards with different types of care and specialties.

Methods {#Sec2}
=======

Patients aged ≥ 18 years and hospitalised for at least 48 h, who developed diarrhoea symptoms while in the hospital and while taking antibiotics, or within 30 days of starting antibiotic therapy, and who agreed to participate in the study, were included in the prospective non-interventional multicentre epidemiological study.

Diarrhoea is defined as liquid stool corresponding to types 5--7 on the Bristol Stool Form Scale, with a frequency of ≥ 3 defecations in succession within ≤ 24 h or with defecation frequency that is higher than normal for a given patient. Under the exclusion criteria, patients could not participate in the study more than once. A stool sample was placed in a sterile container and transported to the local (on-site) microbiology laboratory for an enzyme immunoassay express test (CoproStrip™; SavyonDiagnostics, Israel) for the presence of GDH, toxin A and toxin B of *C. difficile*. The express test interpretation protocol is shown in Table [1](#Tab1){ref-type="table"}.Table 1Interpretation protocol of the enzyme immunoassay express test results for the presence of GDH, toxin A and toxin BResultInterpretationGDH (+), Toxin A (+), Toxin B (−)CDADGDH (+), Toxin A (−), Toxin B (+)CDADGDH (+), Toxin A (+), Toxin B (+)CDADGDH (+), Toxin A (−), Toxin B (−)*C. difficile* colonisationGDH (−), Toxin A (+), Toxin B (+)Invalid test result^a^GDH (−), Toxin A (+), Toxin B (−)Invalid test result^a^GDH (−), Toxin A (−), Toxin B (+)Invalid test result^aa^Patient data with invalid test results were excluded from statistical interpretation

The following patient data were included in the individual electronic registration card: date of birth, sex, main diagnosis leading to hospitalisation according to the International Classification of Diseases, revision 10 (ICD-10), hospitalisation date, characteristics of diarrhoea, information about the date and results of the express test for the presence of GDH, toxin A and toxin B in stool, the type of care provided (surgery, therapy, intensive care) and the medical specialty (gastroenterology, oncohaematology, oncology, etc.).

The primary endpoint, reflecting the presence of CDAD, was the percentage of patients with CDAD among the hospitalised patients with AAD who had an express stool test for GDH and free toxins of *C. difficile*. The secondary endpoints were the percentages of hospitalised patients with CDAD in subgroups classified according to specialty (gastroenterology, oncohaematology, oncology, etc.) and the type of care (surgery, therapy, intensive care). An additional endpoint was the percentage of hospitalised patients with CDAD who had positive express test results for GDH, but negative results for *C. difficile* toxins.

It was planned to include 1230 patients in the study. The sample size, which would ensure accuracy of the primary endpoint was calculated based on the following conditions: a simple random sampling model, width of the 95% confidence interval (CI) not exceeding 5% (2.5% error), risk of obtaining incomplete data below 20%. Statistical analysis was performed using SPSS v22 for Windows operating system. The results were represented as standard variables of descriptive statistics. The study design was taken into account in the statistical analysis by the adjustment of the 95% CI using the methods proposed by the World Health Organization.

The study was conducted according to the principles of the Declaration of Helsinki as well as Good Epidemiological Practice (Guidelines of the International Society for Pharmaceutical Engineering and Good Pharmacy Practice, 2007).

Results {#Sec3}
=======

Characteristics of Patients {#Sec4}
---------------------------

From April 2016 to April 2017, a total of 1245 patients from 12 large inpatient clinics located in Moscow and St Petersburg were enrolled in the study. Data from 81 patients (6.5%) were excluded from the statistical analysis and the description for the following reasons: invalid express test results, including negative results for GDH coinciding with positive results for *C. difficile* toxins (*n* = 60), admission to hospital for less than 48 h (*n* = 10), discrepancy between the express test dates and the study protocol (*n* = 5), violation of the exclusion criteria (*n* = 3), no full-time hospitalisation (day care facilities, *n* = 2), and incomplete patient data (*n* = 1) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Distribution of patients

The analysed data of the 1164 patients \[526 males (45.2%) and 638 females (54.8%)\] are presented. The age ranged from 18 to 95 years (average age, 54.9 years). The distribution of the patients by primary diagnosis is shown in Table [2](#Tab2){ref-type="table"}.Table 2Distribution of patients by primary diagnosisCode (ICD-10)Diagnosis (ICD-10)Number of patientsPatients (%)(A00--B99)Certain infectious and parasitic diseases90.8(C00--D48)Neoplasms38633.2(D50--D89)Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism50.4(E00--E90)Endocrine, nutritional and metabolic diseases564.8(G00--G99)Diseases of the nervous system40.3(I00--I99)Diseases of the circulatory system16814.4(J00--J99)Diseases of the respiratory system756.4(K00--K93)Diseases of the digestive system28824.7(L00--L99)Diseases of the skin and subcutaneous tissue675.8(M00--M99)Diseases of the musculoskeletal system and connective tissue141.2(N00--N99)Diseases of the genitourinary system242.1(O00--O99)Pregnancy, childbirth and the puerperium20.2(Q00--Q99)Certain conditions originating in the perinatal period10.1(R00--R99)Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified60.5(S00--T98)Injury, poisoning and certain other consequences of external causes393.4(V01--Y98)External causes of morbidity and mortality10.1(Z00--Z99)Factors influencing health status and contact with health services191.6Total1164100.0

The diagnoses chiefly responsible for hospitalisation of 72.3% of the patients included neoplasms, diseases of the circulatory system, and diseases of the digestive system. The length of hospitalisation varied from 2 to 188 days, the median being 8 days (1st quartile 5 days, 3rd quartile 15 days). In the majority of cases (1131), the patients were hospitalised for between 2 and 50 days, with 7 patients for over 100 days.

Totals of 522 patients (44.9%) had type 7 diarrhoea on the Bristol Stool Form Scale, 475 patients (40.8%) had type 6 and 167 (14.3%) had type 5. A diarrhoea frequency of 3--8 defecations per day was observed in the majority of patients (944, 81.1%); 15 or more defecations were observed in 27 patients (2.3%).

Primary Endpoint {#Sec5}
----------------

CDAD was diagnosed in 21.7% of patients with AAD (253/1164) according to the express test results (Table [3](#Tab3){ref-type="table"}). The 95% CI for CDAD prevalence, calculated based on the simple random sampling model, was 19.4%, 24.1%. At the same time, the 95% CI adjusted for the study design was significantly wider (14.8%, 28.7%).Table 3Prevalence of positive express test results for GDH and *C. difficile* toxinsResultNumber of patientsPatients (%)GDH (+), Toxin A (+), Toxin B (−)6124.1GDH (+), Toxin A (−), Toxin B (+)8533.6GDH (+), Toxin A (+), Toxin B (+)10742.3Total253100

Secondary Endpoints {#Sec6}
-------------------

CDAD prevalence among the patients with AAD divided into groups by specialty of the provided care is shown in Table [4](#Tab4){ref-type="table"}.Table 4Prevalence of CDAD in the groups of patients with AAD by specialty of the provided careType of careSpecialtyNumber of patients with AADNumber of patients with CDADPatients with CDAD (%)SurgeryVascular8562.5Cardiology9444.4Gastroenterology17847.1General25416.0Gynaecology400.0Hepatology2150.0Neurology17529.4Oncohaematology100.0Oncology2252712.0ENT11100.0Colorectal surgery4375.0Septic surgery2048039.2Thoracic surgery22100.0Thoraco-abdominal surgery600.0Transplantation300.0Trauma10220.0Urology8112.5Total54614326.2TherapyCardiology14428.6Chemotherapy200.0Gastroenterology1942412.4General471531.9Nephrology5360.0Neurology301033.3Oncohaematology1422517.6Oncology2428.3Pulmonology40410.0Rheumatology10440.0Toxicology200.0Total5109117.8Intensive careCardiology7114.3Gastroenterology200.0General20630.0Nephrology100.0Neurology19631.6Oncohaematology5120.0Oncology800.0Colorectal surgery22100.0Toxicology200.0Transplantation4137.3Trauma100.0Total1081917.6Overall total116425321.7

The majority of patients participating were from the departments of surgery (546/1164) and therapy (510/1164). The percentage of CDAD was 26.2% in the surgery patients and 17.8 and 17.6% in the therapy and intensive care patient groups, respectively. The surgical patients were predominantly in oncology (*n* = 225) and septic surgery (*n* = 204) departments. The percentages of CDAD were 12.0% among the \[surgical\] oncology patients and 39.2% in the septic surgical group. The majority of the medical patients were in the departments of gastroenterology (194/510), oncohaematology (142/510) and general medicine (47/510). CDAD prevalence in these departments were 12.4, 17.6 and 31.9%, respectively. The majority of the patients with CDAD in the intensive care units were transplant patients (*n* = 41). The percentage of CDAD in this group was 7.3%.

The prevalence of CDAD in the groups of patients with AAD by specialty is presented in Table [5](#Tab5){ref-type="table"}.Table 5Prevalence of CDAD in the groups of patients with AAD by specialty of the provided careSpecialtyNumber of patientsNumber of patients with CDADPatients with CDAD (%)Vascular8562.5Cardiology30930.0Chemotherapy200.0Gastroenterology2133215.0General922527.2Gynaecology400.0Hepatology2150.0Nephrology6350.0Neurology662131.8Oncohaematology1482617.6Oncology2572911.3ENT11100.0Colorectal surgery6583.3Pulmonology40410.0Septic surgery2048039.2Rheumatology10440.0Thoracic surgery22100.0Thoraco-abdominal surgery600.0Toxicology400.0Transplantation4436.8Trauma11218.2Urology8112.5Total116425321.7

According to the results, more than 75% of all enrolled patients were in the departments of oncology, gastroenterology, septic surgery, oncohaematology, and general medicine. The percentages of patients with CDAD in these departments amounted to 11.3, 15.0, 39.2, 17.6, and 27.2%, respectively.

Other Endpoints {#Sec7}
---------------

Positive GDH express test results were observed in 38.6% of the patients (449/1164), while *C. difficile* did not produce A and B toxins in 16.8% of the cases (196/1164). It should also be noted that the percentage of patients with a CDAD varied among hospitals, from 0 to 44.3% (Table [6](#Tab6){ref-type="table"}).Table 6Prevalence of CDAD at study sitesNumber of patientsNumber of patients with CDADPatients with CDAD (%)1370022727.436857.44201199.551231713.8643614.071272116.581082018.591122825.0107228.61131929.01228012444.3Total116425321.7

A higher percentage of CDAD (26.7--42.9%) was observed in patients ≥ 65 years compared with patients \< 65 years (14.1--17.2%) (Table [7](#Tab7){ref-type="table"}).Table 7Prevalence of CDAD by age groupAge group (years)Number of patientsNumber of patients with CDADPatients with CDAD (%)\< 402763914.140--645249017.265--741764726.775--841406042.9≥ 85481735.4Total116425321.7

Discussion {#Sec8}
==========

The use of antibiotics is a proven risk factor for diarrhoea. According to McFarland, CDAD occurs in 5--39% of patients \[[@CR1]\]. The research of Bartlett and Gilbert published in the 1990s demonstrated that diarrhoea developed in 5--10% of patients receiving ampicillin; 10--25%, amoxicillin/clavulanate; 15--20%, cefixime; and 2--5%, cephalosporins, fluoroquinolones, azithromycin, clarithromycin, erythromycin and tetracycline \[[@CR2], [@CR3]\].

*C. difficile* predominates among the infectious causes of AAD \[[@CR1]--[@CR4]\]. The role of *C. difficile* in the development of CDAD and pseudomembranous colitis was established in 1978. In the majority of cases, the development of pathological conditions was associated with use of clindamycin \[[@CR4]\]. Other pathogens of AAD include *Clostridium perfringens* \[[@CR14]\], *Staphylococcus aureus* \[[@CR15]\], *Klebsiella oxytoca* \[[@CR16]\], and possibly *Candida albicans* \[[@CR17]\].

*C. difficile* is able to produce enterotoxin (toxin A) and cytotoxin (toxin B), which disrupt the function of and damage mucous membranes and, therefore, play a leading role in the pathogenesis of the infectious diseases \[[@CR18], [@CR19]\]. The qualitative and quantitative parameters of toxin production are associated with severity of the disease \[[@CR20], [@CR21]\]. Non-toxin-producing strains of *C. difficile* are capable of colonisation, but do not usually damage the mucous membranes of the gastrointestinal tract \[[@CR22]\].

Infectious diseases caused by *C. difficile* have different manifestations, from the mild form of the disease with few symptoms to a fulminant course of pseudomembranous colitis (toxic megacolon, bowel perforation) \[[@CR6], [@CR23]--[@CR26]\]. Relapse is observed in approximately 10--25% of patients 30 days after successful treatment \[[@CR27], [@CR28]\]. According to a European study, the attributive mortality was 2% in patients with diarrhoea that developed after ≥ 3 days after their hospital stay or in patients with suspected *C. difficile* infection. In another 7% of cases, the infection played a significant role in fatal outcomes \[[@CR6]\].

The few Russian data on CDAD prevalence in patients with AAD obtained in single-centre studies differ markedly. For instance, 28.7% (154/563) and 51.5% (67/130) of cases were reported in general hospitals \[[@CR10], [@CR11]\]. An increase of CDAD prevalence among cancer patients from 15.6% (7/45) in 2011 to 24.2% (57/236) in 2013 was reported \[[@CR12]\]. A high CDAD prevalence was observed in gastroenterology patients, 39.1% (93/238) \[[@CR13]\].

The present study was conducted due to the scarcity of information on CDAD prevalence in the Russian Federation and the lack of relevant Russian multicentre studies. According to the results of the conducted express tests, CDAD was diagnosed in 21.7% of patients with AAD, which corresponds to the international data (15--25%) \[[@CR29]\]. The study also demonstrated pronounced differences in CDAD prevalence between different inpatient facilities (from 0 to 44.3%) and between patient groups by type of care (surgery, 26.2%; therapy, 17.6%; intensive care, 17.8%) and by specialty (septic surgery, 39.2%; general medicine, 27.2%; oncohaematology, 17.2%; gastroenterology, 15.0%; oncology, 11.3%; transplantation, 6.8%). These differences may reflect the local characteristics of CDAD epidemiology. In particular, the researchers at the site with the highest CDAD prevalence (44.3%) also reported a particularly severe contingent of patients and an outbreak of the disease during the study.

The percentage of patients with GDH-positive express test results, but negative results for toxins, was 16.8%, while the total percentage of GDH-positive patients was 38.6%. Thus, about 39% of the patients with AAD participating in the study were colonised with *C. difficile*, whereas about half of the *C. difficile* colonisation cases were accompanied by toxin production and the onset of infection.

Patients age ≥ 65 years demonstrated higher CDAD prevalence (26.7--42.9%) in comparison with the patients \< 65 years (14.1--7.2%). This was expected, since advanced age (≥ 65 years) is one of the known risk factors for the development of CDAD \[[@CR30]\].

The results of this study and previously published Russian epidemiological studies suggest that CDAD is a common complication occurring in Russian hospitals. This makes it more relevant to carefully examine a patient with unexplained diarrhoea when the patient is on antibiotic treatment or within 30 days following such treatment. Significant differences in CDAD prevalence among hospitals and hospital departments may be associated with specific characteristics of the hospitalised patients, the environmental risk factors of *C. difficile*-associated disease and the local approaches to the monitoring of nosocomial infections.

Limitations of the Study {#Sec9}
------------------------

Only large inpatient treatment facilities in the Russian cities with a high population density (Moscow and St Petersburg) participated in the study. This limits the potential for extrapolating the data at the country-wide level.

The pronounced differences in CDAD prevalence rates between the research sites impacted the accuracy of primary endpoint assessment: the 95% CI adjusted for the study design turned out to be wider than the 95% CI based on the simple random sampling model, which was used for sample size calculation during the study planning process.

The express test used in the study has known sensitivity and specificity limitations reducing the accuracy of CDAD diagnosis. In particular, negative results of this laboratory test did not entirely rule out CDAD.

Conclusion {#Sec10}
==========

The prevalence of CDAD among hospitalised patients with AAD amounted to 21.7% (95% CI adjusted for the study design: 14.8%, 28.7%). There were pronounced differences in CDAD prevalence among inpatient care facilities (from 0% to 44.3%) and patient groups by the type of care and specialty.
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